Quantcast
Last updated on April 18, 2014 at 10:45 EDT

Latest antibodies Stories

2014-02-05 12:29:15

The feat bolsters rational vaccine design approach that could also be applied to other challenging viruses including HIV and influenza LA JOLLA, Calif., Feb. 5, 2014 /PRNewswire-USNewswire/ -- Scientists at The Scripps Research Institute (TSRI) have invented a new method for designing artificial proteins, and have used it to make key ingredients for a candidate vaccine against a dangerous virus, respiratory syncytial virus (RSV), a significant cause of infant mortality. The virus has...

2014-02-04 11:53:12

Discovery may have implications for HIV vaccine research WHAT: NIH scientists have discovered a mechanism involved in stabilizing key HIV proteins and thereby concealing sites where some of the most powerful HIV neutralizing antibodies bind, findings with potential implications for HIV vaccine research. Numerous spikes jut out of the surface of HIV, each containing a set of three identical, bulb-shaped proteins called gp120 that can be closed together or spread apart like the petals of...

2014-01-31 23:24:23

OriGene Technologies, Inc. (“OriGene”), one of the industry leaders in producing genome wide products for research and diagnostic applications, has been awarded a contract from the National Cancer Institute (NCI) to develop high affinity anti-peptide antibodies for SISCAPA assays. Rockville, MD (PRWEB) January 31, 2014 Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA), an approach developed by Dr. Leigh Anderson, is a novel technology that can achieve high...

2014-01-22 08:28:34

Patent Provides Coverage for Lpath's Anti-S1P Antibody in the Treatment of a Wide Variety of Ocular Disorders, Including Wet AMD SAN DIEGO, Jan. 22, 2014 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the U.S. Patent and Trademark Office that the company has been issued another key patent supporting its iSONEP(TM) program. The newly issued U.S. patent, No. 8,614,103, is entitled,...

2014-01-13 08:27:35

SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- Fabrus, Inc., a San Diego based antibody discovery company, announced today that it has obtained worldwide exclusive rights to Chimerasome(TM) nanocage technology originally developed by Chimeros, Inc. The foundation of Chimerasome technology is a single protein that can be manipulated to form a spherical protein shell, which can encapsulate drugs and be coupled to antibodies externally, allowing very specific cellular targeting of the...

2014-01-10 11:36:39

A new way to test for the parasite which causes the fatal disease leishmaniasis could help control its spread to humans and stop dogs being needlessly killed in parts of South America A new way to test for the parasite which causes the fatal disease leishmaniasis could help control its spread to humans and stop dogs being needlessly killed in parts of South America. Zoonotic visceral leishmaniasis is a vector-transmitted parasitic infection which can be fatal if left untreated. It...

2014-01-07 08:32:18

SAN FRANCISCO, Jan. 7, 2014 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration agreement with Memorial Sloan-Kettering Cancer Center to use Sutro's proprietary cell-free protein synthesis technology to produce bispecific antibodies that were discovered by Memorial Sloan-Kettering for the...

2014-01-06 23:02:34

In-demand research study “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” worked out by GBI Research has been recently published by Market Publishers Ltd. According to the study, the value of the overall market for mAbs in gastric and esophageal cancers is forecast to touch the USD 766 million mark by 2019. London, UK (PRWEB) January 06, 2014 Currently, esophageal and gastric...

Boosting A Malaria Vaccine
2013-12-27 12:34:32

Brett Smith for redOrbit.com - Your Universe Online According to a study published in the journal PLOS Pathogens on Thursday, a prominent malaria vaccine could be drastically improved by utilizing the right mix of proteins taken from the surface of the virus. The study researchers focused on the virus’ AMA1 protein, which the human body recognizes and uses to stimulate an immune response. However, the protein exists in multiple strains – causing problems for researchers looking to...

2013-12-19 23:23:22

St. George’s to Utilize DNA2.0’s GeneGPS® Expression Technology to Increase Protein Expression in Tobacco for the Production of Therapeutic Antibodies Menlo Park, Calif. (PRWEB) December 19, 2013 DNA2.0 has entered into a research collaboration with the Infection and Immunity Research Centre at St. George’s, University of London, to support the development of plant-based biopharmaceuticals. Professor Julian Ma and his research group at St. George’s have made significant...